Coya Therapeutics (COYA) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Coya Therapeutics (COYA) over the past year, losing 11.0% versus a loss of 20.9%. Coya Therapeutics is the larger company by market cap ($116.1 million vs $111.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | IMUX |
|---|---|---|
| Share price | $4.95 | $8.19 |
| Market cap | $116.12M | $111.75M |
| 1-day change | -0.80% | +8.33% |
| YTD return | -13.97% | +53.37% |
| 1-year return | -20.92% | -10.98% |
| 5-year return | — | -90.55% |
| EPS (TTM) | $-1.07 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $17.43 |
| 52-week low | $3.71 | $5.06 |
| Distance from 52-week high | -36.13% | -53.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +207.27% | +426.13% |
| Average volume | 158.05K | 284.68K |
| Shares outstanding | 23.46M | 13.64M |
| Employees | 8 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
COYA vs IMUX FAQ
Which is bigger, Coya Therapeutics or Immunic?
Coya Therapeutics (COYA) is larger, with a market capitalization of $116.12M compared with $111.75M for Immunic (IMUX).
Which stock has performed better over the past year, COYA or IMUX?
IMUX returned -10.98% over the past 12 months, compared with -20.92% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.